Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 183535, 9 pages
http://dx.doi.org/10.1155/2012/183535
Research Article

Glibenclamide Induces Collagen IV Catabolism in High Glucose-Stimulated Mesangial Cells

Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48202, USA

Received 5 June 2012; Revised 7 August 2012; Accepted 8 August 2012

Academic Editor: Jiro Nakamura

Copyright © 2012 Liping Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. I. Biederman, E. Vera, R. Rankhaniya et al., “Effects of sulfonylureas, α-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes,” Kidney International, vol. 67, no. 2, pp. 554–565, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. W. L. Chiou, G. Robbie, S. M. Chung, T. C. Wu, and C. Ma, “Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66,” Pharmaceutical Research, vol. 15, no. 9, pp. 1474–1479, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius, “From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy,” Diabetes, vol. 57, no. 6, pp. 1439–1445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. H. A. Baccora, P. Cortes, C. Hassett, D. W. Taube, and J. Yee, “Effects of long-term elevated glucose on collagen formation by mesangial cells,” Kidney International, vol. 72, no. 10, pp. 1216–1225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Chen, B. Jim, and F. N. Ziyadeh, “Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up,” Seminars in Nephrology, vol. 23, no. 6, pp. 532–543, 2003. View at Google Scholar · View at Scopus
  6. B. L. Riser, P. Cortes, J. Yee et al., “Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-β,” Journal of the American Society of Nephrology, vol. 9, no. 5, pp. 827–836, 1998. View at Google Scholar · View at Scopus
  7. C. I. Whiteside and J. A. Dlugosz, “Mesangial cell protein kinase C isozyme activation in the diabetic milieu,” American Journal of Physiology. Renal Physiology, vol. 282, no. 6, pp. F975–F980, 2002. View at Google Scholar · View at Scopus
  8. C. G. Nichols, “KATP channels as molecular sensors of cellular metabolism,” Nature, vol. 440, no. 7083, pp. 470–476, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Quast, D. Stephan, S. Bieger, and U. Russ, “The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium,” Diabetes, vol. 53, supplement 3, pp. S156–S164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Sato, H. Nishida, M. Miyazaki, and H. Nakaya, “Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 5, pp. 341–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. F. M. Ashcroft and F. M. Gribble, “Tissue-specific effects of sulfonylureas. Lessons from studies of cloned KATP channels,” Journal of Diabetes and its Complications, vol. 14, no. 4, pp. 192–196, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Metzger, C. Löffler, and U. Quast, “Sulphonylurea binding in rat isolated glomeruli: pharmacological characterization and dependence on cell metabolism and cytoskeleton,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 355, no. 2, pp. 141–149, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Asano, P. Cortes, J. L. Garvin et al., “Characterization of the rat mesangial cell type 2 sulfonylurea receptor,” Kidney International, vol. 55, no. 6, pp. 2289–2298, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Szamosfalvi, P. Cortes, R. Alviani et al., “Putative subunits of the rat mesangial Katp: a type 2B sulfonylurea receptor and an inwardly rectifying K+ channel,” Kidney International, vol. 61, no. 5, pp. 1739–1749, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Cortes, B. L. Riser, K. Asano, A. Rodríguez-barbero, R. G. Narins, and J. Yee, “Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells,” Kidney International, vol. 54, no. 6, pp. 1985–1998, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Giannico, P. Cortes, M. H. Baccora, C. Hassett, D. W. Taube, and J. Yee, “Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells,” American Journal of Physiology. Renal Physiology, vol. 292, no. 1, pp. F57–F65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. D. B. Glass, H.-C. Cheng, L. Mende-Mueller, J. Reed, and D. A. Walsh, “Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein,” Journal of Biological Chemistry, vol. 264, no. 15, pp. 8802–8810, 1989. View at Google Scholar · View at Scopus
  18. D. E. Kleiner and W. G. Stetler-Stevenson, “Quantitative zymography: detection of picogram quantities of gelatinases,” Analytical Biochemistry, vol. 218, no. 2, pp. 325–329, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. G. L. Peterson, “A simplification of the protein assay method of Lowry et al. Which is more generally applicable,” Analytical Biochemistry, vol. 83, no. 2, pp. 346–356, 1977. View at Google Scholar · View at Scopus
  20. A. C. Poncelet and H. W. Schnaper, “Regulation of human mesangial cell collagen expression by transforming growth factor-β1,” American Journal of Physiology. Renal Physiology, vol. 275, no. 3, pp. F458–F466, 1998. View at Google Scholar · View at Scopus
  21. P. Cortes, X. Zhao, B. L. Riser, and R. G. Narins, “Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy,” Kidney International, vol. 51, no. 1, pp. 57–68, 1997. View at Google Scholar · View at Scopus
  22. C. W. Heilig, L. A. Concepcion, B. L. Riser et al., “Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype,” Journal of Clinical Investigation, vol. 96, no. 4, pp. 1802–1814, 1995. View at Google Scholar · View at Scopus
  23. A. K. Ghosh and D. E. Vaughan, “PAI-1 in tissue fibrosis,” Journal of Cellular Physiology, vol. 227, no. 2, pp. 493–507, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. L. J. Ma and A. B. Fogo, “PAI-1 and kidney fibrosis,” Frontiers in Bioscience, vol. 14, no. 6, pp. 2028–2041, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Hagiwara, K. Kaizu, K. Uriu et al., “Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models,” Thrombosis Research, vol. 111, no. 4-5, pp. 301–309, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. B. Nicholas, E. Aguiniga, Y. Ren et al., “Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy,” Kidney International, vol. 67, no. 4, pp. 1297–1307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Huang, W. A. Border, L. Yu, J. Zhang, D. A. Lawrence, and N. A. Noble, “A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 2, pp. 329–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Park, J. Y. Seo, and H. Ha, “Plasminogen activator inhibitor-1 antisense oligodeoxynucleotides abrogate mesangial fibronectin accumulation,” Korean Journal of Physiology and Pharmacology, vol. 14, no. 6, pp. 385–390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Jönsson, B. Hallengren, T. Rydberg, and A. Melander, “Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 3, no. 6, pp. 403–409, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Kirchheiner, J. Brockmöller, I. Meineke et al., “Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers,” Clinical Pharmacology and Therapeutics, vol. 71, no. 4, pp. 286–296, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. K. M. Lee, H. J. Lee, M. K. Kim et al., “Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury,” Atherosclerosis, vol. 207, no. 2, pp. 391–398, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. H. Heaton, W. M. Dlakic, and T. D. Gelehrter, “Posttranscriptional regulation of PAI-I gene expression,” Thrombosis and Haemostasis, vol. 89, no. 6, pp. 959–966, 2003. View at Google Scholar · View at Scopus
  33. S. Seino and T. Shibasaki, “PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis,” Physiological Reviews, vol. 85, no. 4, pp. 1303–1342, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. K. M. Thrailkill, R. C. Bunn, and J. L. Fowlkes, “Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy,” Endocrine, vol. 35, no. 1, pp. 1–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. W. H. Baricos, J. C. Reed, and S. L. Cortez, “Extracellular matrix degradation by cultured mesangial cells: mediators and modulators,” Experimental Biology and Medicine, vol. 228, no. 9, pp. 1018–1022, 2003. View at Google Scholar · View at Scopus
  36. S. V. McLennan, S. K. Y. Martell, and D. K. Yue, “Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy,” Diabetes, vol. 51, no. 8, pp. 2612–2618, 2002. View at Google Scholar · View at Scopus
  37. C. Caenazzo, S. Garbisa, M. Onisto, M. Zampieri, B. Baggio, and G. Gambaro, “Effect of glucose and heparin on mesangial α1(IV)COLL and MMP-2/TIMP-2 mRNA expression,” Nephrology Dialysis Transplantation, vol. 12, no. 3, pp. 443–448, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Singh, R. H. Song, N. Alavi, A. A. Pegoraro, A. K. Singh, and D. J. Leehey, “High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-β1,” Experimental Nephrology, vol. 9, no. 4, pp. 249–257, 2001. View at Google Scholar · View at Scopus
  39. R. H. Song, A. K. Singh, and D. J. Leehey, “Decreased glomerular proteinase activity in the streptozotocin diabetic rat,” American Journal of Nephrology, vol. 19, no. 3, pp. 441–446, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Portik-Dobos, A. K. Harris, W. Song et al., “Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes,” American Journal of Physiology. Regulatory Integrative and Comparative Physiology, vol. 290, no. 2, pp. R435–R441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. W. E. Rodriguez, N. Tyagi, I. G. Joshua et al., “Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus,” American Journal of Physiology. Renal Physiology, vol. 291, no. 3, pp. F694–F701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. S. V. McLennan, D. J. Kelly, A. J. Cox et al., “Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases,” Diabetologia, vol. 45, no. 2, pp. 268–275, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Z. Sun, Y. Wang, Q. Li, Y. J. Tian, M. H. Liu, and Y. H. Yu, “Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats,” Chinese Medical Journal, vol. 119, no. 10, pp. 814–821, 2006. View at Google Scholar · View at Scopus
  44. R. W. Mankhey, C. C. Wells, F. Bhatti, and C. Maric, “17β-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney,” American Journal of Physiology. Regulatory Integrative and Comparative Physiology, vol. 292, no. 2, pp. R769–R777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Zahner, S. Harendza, E. Müller, G. Wolf, F. Thaiss, and R. A. K. Stahl, “Prostaglandin E2 stimulates expression of matrix metalloproteinase 2 in cultured rat mesangial cells,” Kidney International, vol. 51, no. 4, pp. 1116–1123, 1997. View at Google Scholar · View at Scopus
  46. E. Staun-Ram, S. Goldman, and E. Shalev, “Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion,” Reproductive Biology and Endocrinology, vol. 7, no. article no. 135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Katsumoto, T. Shingu, R. Kuwashima, A. Nakata, S. Nomura, and K. Chayama, “Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis,” Circulation Journal, vol. 69, no. 12, pp. 1547–1555, 2005. View at Publisher · View at Google Scholar · View at Scopus